Atlantic Systems

Atlantic Healthcare is a specialist pharmaceutical company focused on developing and commercializing therapies for gastrointestinal (GI) diseases, particularly those with high unmet medical needs. The company's lead product candidate is alicaforsen, an antisense oligonucleotide designed to inhibit the production of ICAM-1, a key protein involved in the inflammatory response. Alicaforsen is currently in Phase 3 clinical development for the treatment of pouchitis, a serious complication of surgery for ulcerative colitis, and has received Orphan Drug designation from both the FDA and EMA. Atlantic Healthcare aims to address the needs of patients with rare and specialist GI conditions through targeted, innovative therapeutic approaches.